Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.5000
+0.0298 (6.34%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Outlook Therapeutics Employees
Outlook Therapeutics had 17 employees as of September 30, 2025. The number of employees decreased by 6 or -26.09% compared to the previous year. That makes Outlook Therapeutics the 38,829th largest employer in the world and 5,654th in the United States.
Employees
17
Change (1Y)
-6
Growth (1Y)
-26.09%
Revenue / Employee
n/a
Profits / Employee
-$3,595,486
Market Cap
121.72M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 17 | -6 | -26.09% |
| Sep 30, 2024 | 23 | -1 | -4.17% |
| Sep 30, 2023 | 24 | 7 | 41.18% |
| Sep 30, 2022 | 17 | 8 | 88.89% |
| Sep 30, 2021 | 9 | 1 | 12.50% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tonix Pharmaceuticals Holding | 142 |
| Voyager Therapeutics | 141 |
| Seer, Inc. | 124 |
| Foghorn Therapeutics | 106 |
| enGene Therapeutics | 82 |
| Acumen Pharmaceuticals | 61 |
| Armata Pharmaceuticals | 61 |
| Spruce Biosciences | 22 |
OTLK News
- 6 days ago - Outlook Therapeutics announces Greg DiPasquale as chief commercial officer - TheFly
- 6 days ago - Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer - GlobeNewsWire
- 9 days ago - Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion - GlobeNewsWire
- 14 days ago - Outlook submits HCPCS Level II application to CMS for J-code for LYTENAVA - TheFly
- 14 days ago - Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg) - GlobeNewsWire
- 23 days ago - Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment - Business Wire
- 4 weeks ago - Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts